1-5 of 5
Mark Erlander
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller, Prapti A. Patel, Alexander I. Spira, Michaela L. Tsai, Errin Samuëlsz, Sandra L. Silberman, Mark Erlander, Eunice S. Wang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6132–6140.
https://doi.org/10.1158/1078-0432.CCR-20-2586
Published: 01 December 2020
View article titled, A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Open the PDF for A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract A43: Plasma-derived circulating tumor DNA (ctDNA) as a surrogate biomarker for treatment response with the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with LDAC or decitabine in acute myeloid leukemia (AML)

Errin Samuelsz, Maya Ridinger, Mark Erlander, Latifa Hassaine, Marion Luebbermann, Brittany Ross
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A43.
https://doi.org/10.1158/1557-3265.LiqBiop20-A43
Published: 01 June 2020
View article titled, Abstract A43: Plasma-derived circulating tumor DNA (ctDNA) as a surrogate biomarker for treatment response with the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with LDAC or decitabine in acute myeloid leukemia (AML)
Journal Articles

Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response

Hatim Husain, Karena Kosco, Saege Hancock, Errin Samuelsz, Shiloh Guerrero, Brian Woodward, Cecile Rose Vibat, Vlada Melnikova, Mark Erlander, Scott Lippman, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1_Supplement): 30.
https://doi.org/10.1158/1557-3265.PMSCLINGEN15-30
Published: 03 January 2016
View article titled, Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response
Journal Articles

A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer

Xiao-Jun Ma, Ranelle Salunga, Sonika Dahiya, Wilson Wang, Erin Carney, Virginie Durbecq, Adrian Harris, Paul Goss, Christos Sotiriou, Mark Erlander, Dennis Sgroi
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2601–2608.
https://doi.org/10.1158/1078-0432.CCR-07-5026
Published: 01 May 2008
View article titled, A Five-Gene Molecular Grade Index and <em>HOXB13:IL17BR</em> Are Complementary Prognostic Factors in Early Stage Breast Cancer
Open the PDF for A Five-Gene Molecular Grade Index and <em>HOXB13:IL17BR</em> Are Complementary Prognostic Factors in Early Stage Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen

Matthew P. Goetz, Vera J. Suman, James N. Ingle, Andrea M. Nibbe, Dan W. Visscher, Carol A. Reynolds, Wilma L. Lingle, Mark Erlander, Xiao-Jun Ma, Dennis C. Sgroi, Edith A. Perez, Fergus J. Couch
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (7): 2080–2087.
https://doi.org/10.1158/1078-0432.CCR-05-1263
Published: 11 April 2006
View article titled, A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen
Open the PDF for A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen in another window